Drugs / BLS-M22
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03789734 | Jun 2019 → Apr 2020 | Duchenne muscular dystrophy | BioLeaders Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLS-M22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03789734 ↗ |
| Action | Inhibit | “BLS-M22 is being developed as an anti-myostatin agent” NCT03789734 ↗ |